073

Association of coronary atherosclerosis diffusion, Framingham score (FRS) and the metabolic syndrome (MS) and its component: an angiography study

Monia Elasmi (1), Wiem Zidi (2), Yosra Zayani (1), Amira Zaroui [Ora-teur] (1), Rachid Mecheanche (1), Sami Mouradi (1), Nezha Kaabachi (1)
(1) Hôpital la Rabta, Explorations Fonctionnelles, Tunis, Tunisie – (2) Hôpital la Rabta, Biochimie, Tunis, Tunisie

Study to evaluate the relationship between conventional assessment of the global cardio-vascular risk by means of FRS and the MS and its different component with the coronary atherosclerosis severity. About 425 consecutives patients undergoing angiographic coronary exploration. The severity of the atherosclerosis diffusion was assessed using a score assessing the number of vessel-segment with atherosclerotic plaque (≥20% luminal vessel), patients were classed into 5 groups. We found a linear correlation between the coronary atherosclerosis diffusion score and the MS and its component (p=0.04 for all factor) and with the mean of the FRS. MS and FSR were assessed respectively for the group score0 at: 47.1%, 10.9±8.1, group score1 at 44.8%, 15±10 , group score 2 at 68.1%, 28±15 , the difference was statistically significant, p=0.002 for the MS , and p=0.003 for the FSR.

Conclusion:Our study showed that increased FRS are associated with the score 3 at 73.3%, 18±10 and score 4 at 62%, 28±15 , the difference 47.1%, 10.9±8.1, group score1 at 44.8%, 15±10 , group score 2 at 68.1%, 28±15 , the difference was statistically significant, p=0.002 for the MS , and p=0.003 for the FSR.

074

Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipid and inflammatory parameters after coronary stenting for acute coronary syndrome

Raphael Poyet [Orateur] (1), Thomas Cuisset (2), F X Brocq (1), Jacques Quilici (2), Corinne Prêre (3), Pierre Jean Moro (2), P E Morange (3), J L Bonnet (2)
(1) HIA Ste Anne, Cardiologie, Toulon, France – (2) AP-HM, CHU La Timone, Cardiologie Interventionnelle, Marseille, France – (3) AP-HP, CHU La Timone, Laboratoire d’Hématologie, Marseille, France

Objective: To compare the effect of high doses of rosuvastatin and atorvastatin on lipidic, inflammatory parameters and platelet response to clopidogrel after coronary stenting for Non ST Elevation Acute Coronary Syndrome (NSTE ACS).

Background: Use of atorvastatin has been reported to decrease significantly the clopidogrel antiplatelet effect because of cytochrome P450 interaction. Rosuvastatin, a recent developed statin is metabolized via a different pathway. We investigated whether the coadministration of high doses of atorvastatin or rosuvastatin for one month in patients with acute coronary syndromes (ACS) could affect the antiplatelet potency of clopidogrel.

Methods and Results: 138 patients undergoing coronary stenting for NSTE ACS were prospectively included and randomized to rosuvastatin 20 mg (n=69) or atorvastatin 80 mg (n=69). They received at discharge 100 mg aspirin and 150 mg clopidogrel. Platelet reactivity indexes VASP and ADP-induced aggregation were used to assess clopidogrel response. After one month, clopidogrel response was similar among patients receiving rosuvastatin and atorvastatin: PRI VASP 44.6±2.5% vs 46±2.3% respectively, p=0.66 and ADP-Ag 53±1.7% vs 50±2.1% respectively , p=0.23. Inflammatory and lipid parameters were similar between the two groups and the number of patients reaching the target LDL cholesterol of less than 2.5 mmol/L was similar in both groups: 74 % (n=51) with rosuvastatin and 71% (n=49) with atorvastatin. P=0.85.

Conclusion: our present study suggests that in high risk patients, high dose of atorvastatin has no negative effect on high maintenance dose of clopidogrel, while providing same benefit on cholesterol lowering.

075

Immediate and long term outcomes of the percutaneous coronary intervention of the ostia of the major epicardial coronary arteries

Leila Abid [Orateur] (1), Majdi Abdennadher (1), Zied Frihka (1), S Mal-lek (1), Mourad Benati (1), Samir Kammoun (2)
(1) Hôpital Hédi Chaker, Cardiologie, Sfax, Tunisie – (2) CHU Hédi Chaker, Sfax, Tunisie

Background: The percutaneous treatment of coronary ostial disease represents a challenge for the interventional cardiologist and is associated with higher procedural and long term complication rates.

Aim of the study: To evaluate the immediate and long term outcomes of the percutaneous coronary intervention of the major coronary artery ostial lesion defined as a lesion arising within 3 mm of the vessel origin (LAD, CX, and RCA).

Methods: A retrospective study on 80 patients, who underwent PCI for ostial lesions of the left anterior descending, left circumflex, and right coronary arteries over a period from 2001 to 2009 in the cardiology department of the University Hedi Chaker Hospital of Sfax.

Results: The mean follow up of our patients was 31.17 months (±27, 5 months). The mean age of our patients was 57.9 years; male predominance was noted with sex ratio 2 /1. The Myocardial infarction (STEMI) was the most common reason for admission (37 patients). The remaining patients have either none elevated ST- Acute Coronary Syndromes (21 patients) nor stable effort angina (22 patients).

The target lesion was the left anterior descending in 72.5%, the right coronary artery in 21.3% and the circumflex artery in 6.3%.

The mean degree of stenosis was 82.6% (± 14.11) with a mean length of 16.30 mm (± 6, 6 mm). The PCI technic was mainly direct stenting in 54.4%, a predilatation before stenting in 30.4% and a post dilatation was necessary in 3.8%. PTCA with balloon only has been practiced in 11.4% of cases. A kissing balloon (LAD, CX) was performed in 18 patients (22.8%).

We used a bare metal stent in 93.1% of cases and drug eluting stent for 6.9% of our population study. 5 PCI were complicated: 2 cases of dissection, 2 effect snow plows (LAD – CX) and one coronary perforation with a procedural complication rate of 6.3%.

42 patients (54.5%) were readmitted after PCI. Target Lesion revascularization (TLR) was 18, 5% and the rate of composite MACE (Death, non fatal MI, TLR) was 30 %.

Conclusion: PCI of ostial narrowings of the major epicardial coronary arteries was relatively safe. However it was associated with a high incidence of adverse long term outcomes.

076

Calcification in HIV-infected patients, assessed by coronary artery calcium score (CACS): the VIHCAC study

Romain Chopard [Orateur]
4, rue Roger Martin du Gard, 25000 Besançon

Background: Human immunodeficiency virus (HIV) – infected patients may be at higher cardiovascular risk than the non-HIV population. The VIHCAC study aimed to evaluate the Coronary Artery Calcium Score (CACS) in comparison with the Framingham Risk Score (FRS) as a predictor of cardiovascular risk.

Methods: Single-center, prospective cross-sectional study of patients with HIV infection for more than 5 years and no history of coronary disease. Cardiovascular risk was estimated by the Framingham Risk Score (FRS). CACS was calculated using the Agatston method, based on coronary multidetector computed tomography results. A CACS ≥10 was defined as abnormal. Interleukin (IL)-6, ultra-sensitive C-reactive protein (us-CRP), glomerular filtration rate (GFR), and fasting lipids were measured at enrolment.

Results: 187 patients (mean age 48.7 years, mean HIV disease duration 12.6 years and mean anti-retrovirus exposure 11.1 years) were explored. FRS was <10% in 113; 10-20% in 66; and >20% in 8. CACS was abnormal in 45 patients (10-100 in 26; 101-300 in 14; and >300 in 5). CACS and FRS correlated poorly (r=0.15, p=0.04). Patients with abnormal CACS were older (53.1 vs. 47.4 years, p=0.0001), had lower GFR (85.7 vs. 98.0 ml/min, p=0.02), and

© Elsevier Masson SAS. All rights reserved.
higher LDL cholesterol (13.7 vs. 12.8 mg/dL, $p=0.07$). By contrast, there were no differences between the two groups as regards duration of HIV infection, time of exposure to ARVs, (whether considered as a whole or by class), us-CRP, or IL-6. Of the 45 patients with an abnormal CACS, 41 (91.1%) had FRS <20% and would not have been eligible for cardiovascular prevention treatment. These 41 patients represented 22.9% of all patients with FRS <20%. None of the 5 patients with CACS > 300 had been identified as high cardiovascular risk patients by FRS.

**Conclusion:** In HIV-infected patients, CACS identified presence of coronary atherosclerosis in 22.9% of patients who were deemed to be at low to intermediate cardiovascular risk based on FRS.

077

Do platelet activity assessment and genotyping help predict outcome in real world management of patients with ACS?

Nidhal Ben Moussa Nidhal [Orateur] , Salem Abdesselem

**Hôpital la Rabta Tunis, Tunis, Tunisie**

**Purpose:** it has been postulated that outcome of poor metabolizers of clopidogrel may be worse in ACS patients. Data about the interest of assessing platelet reactivity and genotyping in predicting outcome of patients with ACS taking clopidogrel is still conflicting.

**Methods:** Prospectively, 120 successive patients (76.7% men, mean age 60±12.2 years) with ACS 45% STEMI were included. Patients were excluded if not eligible to clopidogrel therapy or to the platelet activity test. Patients were managed according to ESC guidelines. Platelet activity was assessed by a VerifyNow P2Y12 test more than 24h after a 600mg clopidogrel loading dose. DNA was extracted for genotyping of CYP1A1 and CYP2C19 (*1,*2,*3),MACE (death, infarction, stroke, coronary revascularization) was assessed at 6 months.

**Results:** poor platelet inhibition (PRU>230) was noted 54 (46.6%) patients. CYP1A1 and CYP2C19 low metabolizers (homo and heterozygosis) were respectively 23.1% and 37.5%. MACE at 6 months was noted in 15 (12.5%) patients. No significant correlation was found between MACE and platelet reactivity test nor MACE and genotypes CYP1A1 and CYP2C19. Combination of platelet response and resistant genotypes didn’t help to predict MACE.

**Conclusion:** despite the high rates of poor responders to clopidogrel in this study, assessed by the verify now P2Y12 test and by genotyping (CYP1A1 and CYP2C19), no correlation has been found with MACE at 6 months.

078

“Litigious” exercise training: contribution of myocardial scintigraphy

Nadia Diab [Orateur] (1), Rachid Merghit (1), Amira Kherifli (1), Fatima Menad (2), Sami Nacer Khodja (2), Ali Chaalal (2), Hassene Boulama (1), Ilies Bouguelin (1), Aziz Zentati (2), El Mehdi Hafif (2), Naima Adjroud (1)

**Hôpital Central de l’Armée, Médecine Nucléaire, Alger, Algérie – (2) Hôpital Militaire Avicenne Marrakech Mar, Cardiologie, Marrakech, Maroc – (3) Hôpital Ibn Tofail, Cardiologie, Marrakech, Maroc**

**Introduction:** In front of an important request for examination of myocardial scintigraphy following a test of “litigious” effort, we are propose to assess the real work futurism with an aim of answering the question suggested in title, in referent with the results of the myocardial tomoscintigraphy. Materials and methods: Between January 2008 and May 2010, we investigated 186 consecutive patients presenting of the coronary risk factors addressed for myocardial tomoscintigraphy in front of a test of litigious effort on the electric level carried out within the framework of a search for quiet ischemia. Within the service of nuclear medicine all the patients profited from a test of effort carried out within the framework of a search for quiet ischemia. Within the service of nuclear medicine all the patients profited from a test of effort carried out within the framework of a search for quiet ischemia. Within the service of nuclear medicine all the patients profited from a test of effort carried out within the framework of a search for quiet ischemia.

**Purpose:** to establish the myocarvtical perfusionnal of the young subject. Moroccan experience

Laila Bendriss [Orateur] (1), Sara Lamzarraf (2), Mustapha Ek Hattaoui (3), Ali Khatouri (4)

**Hôpital Militaire Avicenne Marrakech Mar, Cardiologie, Marrakech, Maroc – (2) Hôpital Ibn Tofail, Cardiologie, Marrakech, Maroc – (3) Hôpital Ibn Tofail, Cardiologie, Marrakech, Maroc – (4) Hôpital Militaire Avicenne Marrakech Mar, Cardiologie, Marrakech, Maroc**

**Purpose:** The aim of this work is to study the specific epidemiological, clinical, angiographic and evolving myocardial infarction (MI) of the young subject.

**Materials and methods:** It is a retrospective study ruled in the two services of cardiology of the UHC Mohammed VI de Marrakech from January 2005 to October 2009. We included the patients admitted for MI and paired them in two groups: group 1 composed of young patients under 45 years and group 2 of old patients beyond these age limits. Patients in both groups were investigated focusing in epidemiological, clinical, angiographic and evolving myocardial infarction (MI) of the young subject.

**Conclusions:** Conversely to what has been demonstrated for cTnI, no significant difference in AUC was found when Copeptin/cTnI was compared to cTnI alone. This can be explained by the limited set of patients and the relative good result of cTnI AUC. Only combined use of copeptin in negative cTnI patients might help in ruling out AMI because of its good NPV and hence improve triage of patients presenting with chest pain in ED.

080

The myocardial infarction of the young subject. Moroccan experience

Laila Bendriss [Orateur] (1), Sara Lamzarraf (2), Mustapha Ek Hattaoui (3), Ali Khatouri (4)

**Hôpital Militaire Avicenne Marrakech Mar, Cardiologie, Marrakech, Maroc – (2) Hôpital Ibn Tofail, Cardiologie, Marrakech, Maroc – (3) Hôpital Ibn Tofail, Cardiologie, Marrakech, Maroc – (4) Hôpital Militaire Avicenne Marrakech Mar, Cardiologie, Marrakech, Maroc**

**Purpose:** The aim of this work is to study the specific epidemiological, clinical, angiographic and evolving myocardial infarction (MI) of the young subject.

**Materials and methods:** It is a retrospective study ruled in the two services of cardiology of the UHC Mohammed VI de Marrakech from January 2005 to October 2009. We included the patients admitted for MI and paired them in two groups: group 1 composed of young patients under 45 years and group 2 of old patients beyond these age limits. Patients in both groups were investigated focusing in epidemiological, clinical, angiographic and evolving myocardial infarction (MI) of the young subject.

**Conclusions:** Conversely to what has been demonstrated for cTnI, no significant difference in AUC was found when Copeptin/cTnI was compared to cTnI alone. This can be explained by the limited set of patients and the relative good result of cTnI AUC. Only combined use of copeptin in negative cTnI patients might help in ruling out AMI because of its good NPV and hence improve triage of patients presenting with chest pain in ED.